Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure

Edward P. Havranek, Ignatius Thomas, William B. Smith, George A. Ponce, Martin Busker, Mark A. Munger, Robert A. Wolf

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

OBJECTIVES: The primary purpose of this study was to determine the acute and long-term hemodynamic and clinical effects of irbesartan in patients with heart failure. BACKGROUND: Inhibition of angiotensin II production by angiotensin-converting enzyme (ACE) inhibitors reduces morbidity and mortality in patients with heart failure. Irbesartan is an orally active antagonist of the angiotensin II AT 1 receptor subtype with potential efficacy in heart failure. METHODS: Two hundred eighteen patients with symptomatic heart failure (New York Heart Association [NYHA] class II-IV) and left ventricular ejection fraction ≤40% participated in the study. Serial hemodynamic measurements were made over 24 h following randomization to irbesartan 12.5 mg, 37.5 mg, 75 mg, 150 mg or placebo. After the first dose of study medication, patients receiving placebo were reallocated to one of the four irbesartan doses, treatment was continued for 12 weeks and hemodynamic measurements were repeated. RESULTS: Irbesartan induced significant dose-related decreases in pulmonary capillary wedge pressure (average change -5.9 ± 0.9 mm Hg and -5.3 ± 0.9 mm Hg for irbesartan 75 mg and 150 mg, respectively) after 12 weeks of therapy without causing reflex tachycardia and without increasing plasma norepinephrine. The neurohormonal effects of irbesartan were highly variable and none of the changes was statistically significant. There was a significant dose-related decrease in the percentage of patients discontinuing study medication because of worsening heart failure. Irbesartan was well tolerated without evidence of dose-related cough or azotemia. CONCLUSIONS: Irbesartan, at once-daily doses of 75 mg and 150 mg, induced sustained hemodynamic improvement and prevented worsening heart failure.

Original languageEnglish (US)
Pages (from-to)1174-1181
Number of pages8
JournalJournal of the American College of Cardiology
Volume33
Issue number5
DOIs
StatePublished - Apr 1 1999

Fingerprint

irbesartan
Heart Failure
Hemodynamics
Angiotensin II
Placebos
Azotemia
Pulmonary Wedge Pressure

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. / Havranek, Edward P.; Thomas, Ignatius; Smith, William B.; Ponce, George A.; Busker, Martin; Munger, Mark A.; Wolf, Robert A.

In: Journal of the American College of Cardiology, Vol. 33, No. 5, 01.04.1999, p. 1174-1181.

Research output: Contribution to journalArticle

Havranek, Edward P. ; Thomas, Ignatius ; Smith, William B. ; Ponce, George A. ; Busker, Martin ; Munger, Mark A. ; Wolf, Robert A. / Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. In: Journal of the American College of Cardiology. 1999 ; Vol. 33, No. 5. pp. 1174-1181.
@article{cb83eade0d634226b883ce931c54b735,
title = "Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure",
abstract = "OBJECTIVES: The primary purpose of this study was to determine the acute and long-term hemodynamic and clinical effects of irbesartan in patients with heart failure. BACKGROUND: Inhibition of angiotensin II production by angiotensin-converting enzyme (ACE) inhibitors reduces morbidity and mortality in patients with heart failure. Irbesartan is an orally active antagonist of the angiotensin II AT 1 receptor subtype with potential efficacy in heart failure. METHODS: Two hundred eighteen patients with symptomatic heart failure (New York Heart Association [NYHA] class II-IV) and left ventricular ejection fraction ≤40{\%} participated in the study. Serial hemodynamic measurements were made over 24 h following randomization to irbesartan 12.5 mg, 37.5 mg, 75 mg, 150 mg or placebo. After the first dose of study medication, patients receiving placebo were reallocated to one of the four irbesartan doses, treatment was continued for 12 weeks and hemodynamic measurements were repeated. RESULTS: Irbesartan induced significant dose-related decreases in pulmonary capillary wedge pressure (average change -5.9 ± 0.9 mm Hg and -5.3 ± 0.9 mm Hg for irbesartan 75 mg and 150 mg, respectively) after 12 weeks of therapy without causing reflex tachycardia and without increasing plasma norepinephrine. The neurohormonal effects of irbesartan were highly variable and none of the changes was statistically significant. There was a significant dose-related decrease in the percentage of patients discontinuing study medication because of worsening heart failure. Irbesartan was well tolerated without evidence of dose-related cough or azotemia. CONCLUSIONS: Irbesartan, at once-daily doses of 75 mg and 150 mg, induced sustained hemodynamic improvement and prevented worsening heart failure.",
author = "Havranek, {Edward P.} and Ignatius Thomas and Smith, {William B.} and Ponce, {George A.} and Martin Busker and Munger, {Mark A.} and Wolf, {Robert A.}",
year = "1999",
month = "4",
day = "1",
doi = "10.1016/S0735-1097(98)00695-0",
language = "English (US)",
volume = "33",
pages = "1174--1181",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure

AU - Havranek, Edward P.

AU - Thomas, Ignatius

AU - Smith, William B.

AU - Ponce, George A.

AU - Busker, Martin

AU - Munger, Mark A.

AU - Wolf, Robert A.

PY - 1999/4/1

Y1 - 1999/4/1

N2 - OBJECTIVES: The primary purpose of this study was to determine the acute and long-term hemodynamic and clinical effects of irbesartan in patients with heart failure. BACKGROUND: Inhibition of angiotensin II production by angiotensin-converting enzyme (ACE) inhibitors reduces morbidity and mortality in patients with heart failure. Irbesartan is an orally active antagonist of the angiotensin II AT 1 receptor subtype with potential efficacy in heart failure. METHODS: Two hundred eighteen patients with symptomatic heart failure (New York Heart Association [NYHA] class II-IV) and left ventricular ejection fraction ≤40% participated in the study. Serial hemodynamic measurements were made over 24 h following randomization to irbesartan 12.5 mg, 37.5 mg, 75 mg, 150 mg or placebo. After the first dose of study medication, patients receiving placebo were reallocated to one of the four irbesartan doses, treatment was continued for 12 weeks and hemodynamic measurements were repeated. RESULTS: Irbesartan induced significant dose-related decreases in pulmonary capillary wedge pressure (average change -5.9 ± 0.9 mm Hg and -5.3 ± 0.9 mm Hg for irbesartan 75 mg and 150 mg, respectively) after 12 weeks of therapy without causing reflex tachycardia and without increasing plasma norepinephrine. The neurohormonal effects of irbesartan were highly variable and none of the changes was statistically significant. There was a significant dose-related decrease in the percentage of patients discontinuing study medication because of worsening heart failure. Irbesartan was well tolerated without evidence of dose-related cough or azotemia. CONCLUSIONS: Irbesartan, at once-daily doses of 75 mg and 150 mg, induced sustained hemodynamic improvement and prevented worsening heart failure.

AB - OBJECTIVES: The primary purpose of this study was to determine the acute and long-term hemodynamic and clinical effects of irbesartan in patients with heart failure. BACKGROUND: Inhibition of angiotensin II production by angiotensin-converting enzyme (ACE) inhibitors reduces morbidity and mortality in patients with heart failure. Irbesartan is an orally active antagonist of the angiotensin II AT 1 receptor subtype with potential efficacy in heart failure. METHODS: Two hundred eighteen patients with symptomatic heart failure (New York Heart Association [NYHA] class II-IV) and left ventricular ejection fraction ≤40% participated in the study. Serial hemodynamic measurements were made over 24 h following randomization to irbesartan 12.5 mg, 37.5 mg, 75 mg, 150 mg or placebo. After the first dose of study medication, patients receiving placebo were reallocated to one of the four irbesartan doses, treatment was continued for 12 weeks and hemodynamic measurements were repeated. RESULTS: Irbesartan induced significant dose-related decreases in pulmonary capillary wedge pressure (average change -5.9 ± 0.9 mm Hg and -5.3 ± 0.9 mm Hg for irbesartan 75 mg and 150 mg, respectively) after 12 weeks of therapy without causing reflex tachycardia and without increasing plasma norepinephrine. The neurohormonal effects of irbesartan were highly variable and none of the changes was statistically significant. There was a significant dose-related decrease in the percentage of patients discontinuing study medication because of worsening heart failure. Irbesartan was well tolerated without evidence of dose-related cough or azotemia. CONCLUSIONS: Irbesartan, at once-daily doses of 75 mg and 150 mg, induced sustained hemodynamic improvement and prevented worsening heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0033117190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033117190&partnerID=8YFLogxK

U2 - 10.1016/S0735-1097(98)00695-0

DO - 10.1016/S0735-1097(98)00695-0

M3 - Article

C2 - 10193713

AN - SCOPUS:0033117190

VL - 33

SP - 1174

EP - 1181

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 5

ER -